Shares of Exact Sciences (Nasdaq: EXAS) moved higher today after the company was featured in a weekend report by Barron’s. The company is developing a test that can detect colon cancers with more accuracy than screenings that are currently in use. If the test is eventually approved by the FDA, Exact Sciences could be acquired for upward of $20 per share, Barron's said.

Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.